Skip to main content
Erschienen in: Targeted Oncology 1/2010

01.03.2010 | Review

Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy

verfasst von: Anwar R. Padhani, Aftab Alam Khan

Erschienen in: Targeted Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

There is an increasing awareness that anatomical approaches based on measurements of tumor size have significant limitations for assessing therapy response. Functional imaging techniques are increasing being used to monitor response to therapies with novel mechanisms of action, often predicting the success of therapy before conventional measurements have changed. Dynamic contrast-enhanced and diffusion magnetic resonance imaging (MRI) are the most advanced in their evidence base, and in this manuscript we focus on them as response parameters. Technology, data gathering methods, and current limitations for these techniques are addressed. With few exceptions, most studies shows that successful treatment is reflected by increases in tumor water diffusion values visible as increased apparent diffusion coefficient values. Most response assessment studies also show that successful treatment results in decreases in tumor vascularization and microvessel permeability.
Literatur
1.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
2.
Zurück zum Zitat Husband JE, Schwartz LH, Spencer J et al (2004) Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256–2260PubMed Husband JE, Schwartz LH, Spencer J et al (2004) Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256–2260PubMed
3.
Zurück zum Zitat Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764PubMedCrossRef Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764PubMedCrossRef
4.
Zurück zum Zitat Nathan P, Judson I, Padhani A et al (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26:3550CrossRef Nathan P, Judson I, Padhani A et al (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26:3550CrossRef
5.
Zurück zum Zitat Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRef Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRef
6.
Zurück zum Zitat Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef
7.
Zurück zum Zitat Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799PubMedCrossRef Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799PubMedCrossRef
8.
Zurück zum Zitat Workman P, Aboagye EO, Chung Y-L et al (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98:580–598PubMedCrossRef Workman P, Aboagye EO, Chung Y-L et al (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98:580–598PubMedCrossRef
9.
Zurück zum Zitat Weber WA, Czernin J, Phelps ME et al (2008) Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5:44–54PubMedCrossRef Weber WA, Czernin J, Phelps ME et al (2008) Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5:44–54PubMedCrossRef
10.
Zurück zum Zitat Schaefer NG, Taverna C, Strobel K et al (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology 244:257–262PubMedCrossRef Schaefer NG, Taverna C, Strobel K et al (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology 244:257–262PubMedCrossRef
11.
Zurück zum Zitat Bahri S, Chen JH, Mehta RS et al (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 16:1619–1628PubMedCrossRef Bahri S, Chen JH, Mehta RS et al (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 16:1619–1628PubMedCrossRef
13.
Zurück zum Zitat Hu LS, Baxter LC, Smith KA et al (2008) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol. doi:10.3174/ajnr.A1377 Hu LS, Baxter LC, Smith KA et al (2008) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol. doi:10.​3174/​ajnr.​A1377
14.
Zurück zum Zitat Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425–437PubMedCrossRef Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425–437PubMedCrossRef
15.
Zurück zum Zitat Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2):24S–42SPubMedCrossRef Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2):24S–42SPubMedCrossRef
16.
Zurück zum Zitat Nakanishi K, Kobayashi M, Nakaguchi K et al (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 6:147–155PubMedCrossRef Nakanishi K, Kobayashi M, Nakaguchi K et al (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 6:147–155PubMedCrossRef
17.
Zurück zum Zitat Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635PubMedCrossRef Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635PubMedCrossRef
18.
Zurück zum Zitat Patterson DM, Padhani AR, Collins DJ (2008) Technology Insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 5(4):220–233PubMedCrossRef Patterson DM, Padhani AR, Collins DJ (2008) Technology Insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 5(4):220–233PubMedCrossRef
19.
Zurück zum Zitat Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMed Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMed
20.
Zurück zum Zitat Stejskal EO, Tanner J (1965) Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42:288–292CrossRef Stejskal EO, Tanner J (1965) Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42:288–292CrossRef
21.
Zurück zum Zitat Le Bihan D, Breton E, Lallemand D et al (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497–505PubMed Le Bihan D, Breton E, Lallemand D et al (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497–505PubMed
22.
Zurück zum Zitat Niendorf T, Dijkhuizen RM, Norris DG et al (1996) Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging. Magn Reson Med 36:847–857PubMedCrossRef Niendorf T, Dijkhuizen RM, Norris DG et al (1996) Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging. Magn Reson Med 36:847–857PubMedCrossRef
23.
Zurück zum Zitat Taouli B, Vilgrain V, Dumont E et al (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226:71–78PubMedCrossRef Taouli B, Vilgrain V, Dumont E et al (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226:71–78PubMedCrossRef
24.
Zurück zum Zitat Koh DM, Brown G, Riddell AM et al (2008) Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 18:903–910PubMedCrossRef Koh DM, Brown G, Riddell AM et al (2008) Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 18:903–910PubMedCrossRef
25.
Zurück zum Zitat Parikh T, Drew SJ, Lee VS et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822PubMedCrossRef Parikh T, Drew SJ, Lee VS et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822PubMedCrossRef
26.
Zurück zum Zitat Sumi M, Sakihama N, Sumi T (2003) Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 24:1627–1634PubMed Sumi M, Sakihama N, Sumi T (2003) Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 24:1627–1634PubMed
27.
Zurück zum Zitat Yoshikawa MI, Ohsumi S, Sugata S et al (2008) Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med 26:222–226PubMedCrossRef Yoshikawa MI, Ohsumi S, Sugata S et al (2008) Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med 26:222–226PubMedCrossRef
28.
Zurück zum Zitat Manenti G, Di Roma M, Mancino S et al (2008) Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med (Torino) 113:199–213CrossRef Manenti G, Di Roma M, Mancino S et al (2008) Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med (Torino) 113:199–213CrossRef
29.
Zurück zum Zitat Hayashida Y, Hirai T, Morishita S et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425PubMed Hayashida Y, Hirai T, Morishita S et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425PubMed
30.
Zurück zum Zitat Humphries PD, Sebire NJ, Siegel MJ et al (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848–854PubMedCrossRef Humphries PD, Sebire NJ, Siegel MJ et al (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848–854PubMedCrossRef
31.
Zurück zum Zitat Zelhof B, Pickles M, Liney G et al (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103:883–888PubMedCrossRef Zelhof B, Pickles M, Liney G et al (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103:883–888PubMedCrossRef
32.
Zurück zum Zitat Liu Y, Bai R, Sun H et al (2009) Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. J Comput Assist Tomogr 33:858–862PubMedCrossRef Liu Y, Bai R, Sun H et al (2009) Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. J Comput Assist Tomogr 33:858–862PubMedCrossRef
33.
Zurück zum Zitat Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60PubMedCrossRef Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60PubMedCrossRef
34.
Zurück zum Zitat Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828–836PubMedCrossRef Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828–836PubMedCrossRef
35.
Zurück zum Zitat Wang XZ, Wang B, Gao ZQ et al (2009) Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 29:1360–1366PubMedCrossRef Wang XZ, Wang B, Gao ZQ et al (2009) Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 29:1360–1366PubMedCrossRef
36.
Zurück zum Zitat Calvar JA, Meli FJ, Romero C et al (2005) Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol 72:273–280PubMedCrossRef Calvar JA, Meli FJ, Romero C et al (2005) Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol 72:273–280PubMedCrossRef
37.
Zurück zum Zitat Arvinda HR, Kesavadas C, Sarma PS et al (2009) Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 94:87–96PubMedCrossRef Arvinda HR, Kesavadas C, Sarma PS et al (2009) Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 94:87–96PubMedCrossRef
38.
Zurück zum Zitat Geschwind JF, Artemov D, Abraham S et al (2000) Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11:1245–1255PubMedCrossRef Geschwind JF, Artemov D, Abraham S et al (2000) Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11:1245–1255PubMedCrossRef
39.
Zurück zum Zitat Kim H, Morgan DE, Zeng H et al (2008) Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 248:844–851PubMedCrossRef Kim H, Morgan DE, Zeng H et al (2008) Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 248:844–851PubMedCrossRef
40.
Zurück zum Zitat Liimatainen T, Hakumaki JM, Kauppinen RA et al (2009) Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 22:272–279PubMedCrossRef Liimatainen T, Hakumaki JM, Kauppinen RA et al (2009) Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 22:272–279PubMedCrossRef
41.
Zurück zum Zitat Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef
42.
Zurück zum Zitat Hamstra D, Rehemtulla A, BD R (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef Hamstra D, Rehemtulla A, BD R (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef
43.
Zurück zum Zitat Pickles MD, Gibbs P, Lowry M et al (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843–847PubMedCrossRef Pickles MD, Gibbs P, Lowry M et al (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843–847PubMedCrossRef
44.
Zurück zum Zitat Yankeelov TE, Lepage M, Chakravarthy A et al (2007) Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25:1–13PubMedCrossRef Yankeelov TE, Lepage M, Chakravarthy A et al (2007) Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25:1–13PubMedCrossRef
45.
Zurück zum Zitat Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837PubMedCrossRef Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837PubMedCrossRef
46.
Zurück zum Zitat Kamel IR, Rayes DK, Liapi E et al (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18:49–56PubMedCrossRef Kamel IR, Rayes DK, Liapi E et al (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18:49–56PubMedCrossRef
47.
Zurück zum Zitat Cui Y, Zhang XP, Sun YS et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900PubMedCrossRef Cui Y, Zhang XP, Sun YS et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900PubMedCrossRef
48.
Zurück zum Zitat Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 16:2637–2643PubMedCrossRef Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 16:2637–2643PubMedCrossRef
49.
Zurück zum Zitat Uhl M, Saueressig U, van Buiren M et al (2006) Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618–623PubMedCrossRef Uhl M, Saueressig U, van Buiren M et al (2006) Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618–623PubMedCrossRef
50.
Zurück zum Zitat Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529PubMedCrossRef Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529PubMedCrossRef
51.
Zurück zum Zitat Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094–1100PubMedCrossRef Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094–1100PubMedCrossRef
52.
Zurück zum Zitat Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394PubMedCrossRef Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394PubMedCrossRef
53.
Zurück zum Zitat Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedCrossRef Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedCrossRef
54.
Zurück zum Zitat Schaefer PW, Grant PE, Gonzalez RG (2000) Diffusion-weighted MR imaging of the brain. Radiology 217:331–345PubMed Schaefer PW, Grant PE, Gonzalez RG (2000) Diffusion-weighted MR imaging of the brain. Radiology 217:331–345PubMed
55.
Zurück zum Zitat Ries M, Jones RA, Basseau F et al (2001) Diffusion tensor MRI of the human kidney. J Magn Reson Imaging 14:42–49PubMedCrossRef Ries M, Jones RA, Basseau F et al (2001) Diffusion tensor MRI of the human kidney. J Magn Reson Imaging 14:42–49PubMedCrossRef
56.
57.
Zurück zum Zitat Oostendorp M, Post MJ, Backes WH (2009) Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology 251:317–335PubMedCrossRef Oostendorp M, Post MJ, Backes WH (2009) Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology 251:317–335PubMedCrossRef
58.
Zurück zum Zitat Kety S (1960) Measurement of local blood flow by the exchange of an inert, diffusible substance. Methods Med Res 8:228–236 Kety S (1960) Measurement of local blood flow by the exchange of an inert, diffusible substance. Methods Med Res 8:228–236
59.
Zurück zum Zitat Kety S (1960) Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow. Meth Med Res 8:223–227 Kety S (1960) Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow. Meth Med Res 8:223–227
60.
Zurück zum Zitat Tofts P, Brix G, Buckley D et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232PubMedCrossRef Tofts P, Brix G, Buckley D et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232PubMedCrossRef
61.
Zurück zum Zitat Wilkinson ID, Jellineck DA, Levy D et al (2006) Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery 58:640–646, discussion 640–646PubMedCrossRef Wilkinson ID, Jellineck DA, Levy D et al (2006) Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery 58:640–646, discussion 640–646PubMedCrossRef
62.
Zurück zum Zitat O’Connor JP, Carano RA, Clamp AR et al (2009) Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 15:6674–6682PubMedCrossRef O’Connor JP, Carano RA, Clamp AR et al (2009) Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 15:6674–6682PubMedCrossRef
63.
Zurück zum Zitat Lankester KJ, Maxwell RJ, Pedley RB et al (2007) Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 30:453–460PubMed Lankester KJ, Maxwell RJ, Pedley RB et al (2007) Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 30:453–460PubMed
64.
Zurück zum Zitat Lankester KJ, Taylor JN, Stirling JJ et al (2007) Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 25:796–805PubMedCrossRef Lankester KJ, Taylor JN, Stirling JJ et al (2007) Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 25:796–805PubMedCrossRef
65.
Zurück zum Zitat Leach MO, Brindle KM, Evelhoch JL et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599–1610PubMedCrossRef Leach MO, Brindle KM, Evelhoch JL et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599–1610PubMedCrossRef
66.
Zurück zum Zitat Lankester KJ, Taylor NJ, Stirling JJ et al (2005) Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer 93:979–985PubMedCrossRef Lankester KJ, Taylor NJ, Stirling JJ et al (2005) Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer 93:979–985PubMedCrossRef
67.
Zurück zum Zitat Thukral A, Thomasson DM, Chow CK et al (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab–initial experience. Radiology 244:727–735PubMedCrossRef Thukral A, Thomasson DM, Chow CK et al (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab–initial experience. Radiology 244:727–735PubMedCrossRef
68.
Zurück zum Zitat Walker-Samuel S, Parker CC, Leach MO et al (2007) Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 52:75–89PubMedCrossRef Walker-Samuel S, Parker CC, Leach MO et al (2007) Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 52:75–89PubMedCrossRef
69.
Zurück zum Zitat Taylor NJ, Tunariu N, Stirling JJ et al (2009) Non-enhancing pixels: a specific additional DCE-MRI kinetic parameter for assessing antivascular effects of anti-angiogenic and vascular disruptive agents. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine, 16th Scientific Meeting and Exhibition, Honolulu:2262 Taylor NJ, Tunariu N, Stirling JJ et al (2009) Non-enhancing pixels: a specific additional DCE-MRI kinetic parameter for assessing antivascular effects of anti-angiogenic and vascular disruptive agents. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine, 16th Scientific Meeting and Exhibition, Honolulu:2262
70.
Zurück zum Zitat Dyke JP, Panicek DM, Healey JH et al (2003) Osteogenic and Ewing sarcomas: estimation of necrotic fraction = induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228:271–278PubMedCrossRef Dyke JP, Panicek DM, Healey JH et al (2003) Osteogenic and Ewing sarcomas: estimation of necrotic fraction = induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228:271–278PubMedCrossRef
71.
Zurück zum Zitat Schlemmer HP, Merkle J, Grobholz R et al (2004) Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309–317PubMedCrossRef Schlemmer HP, Merkle J, Grobholz R et al (2004) Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309–317PubMedCrossRef
72.
Zurück zum Zitat Padhani AR, Dzik-Jurasz A (2004) Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 15:41–57PubMedCrossRef Padhani AR, Dzik-Jurasz A (2004) Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 15:41–57PubMedCrossRef
73.
Zurück zum Zitat Ferrier MC, Sarin H, Fung SH et al (2007) Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9:546–555PubMedCrossRef Ferrier MC, Sarin H, Fung SH et al (2007) Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9:546–555PubMedCrossRef
74.
Zurück zum Zitat Eby PR, Partridge SC, White SW et al (2008) Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 15:1246–1254PubMedCrossRef Eby PR, Partridge SC, White SW et al (2008) Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 15:1246–1254PubMedCrossRef
75.
Zurück zum Zitat Niermann KJ, Fleischer AC, Huamani J et al (2007) Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26:749–756PubMed Niermann KJ, Fleischer AC, Huamani J et al (2007) Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26:749–756PubMed
76.
Zurück zum Zitat Galban CJ, Chenevert TL, Meyer CR et al (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572–576PubMedCrossRef Galban CJ, Chenevert TL, Meyer CR et al (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572–576PubMedCrossRef
77.
Zurück zum Zitat Barentsz JO, Berger-Hartog O, Witjes JA et al (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797PubMed Barentsz JO, Berger-Hartog O, Witjes JA et al (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797PubMed
78.
Zurück zum Zitat Ah-See ML, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589PubMedCrossRef Ah-See ML, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589PubMedCrossRef
79.
Zurück zum Zitat Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361–374PubMedCrossRef Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361–374PubMedCrossRef
80.
Zurück zum Zitat Reddick WE, Taylor JS, Fletcher BD (1999) Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10:277–285PubMedCrossRef Reddick WE, Taylor JS, Fletcher BD (1999) Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10:277–285PubMedCrossRef
81.
Zurück zum Zitat de Lussanet QG, Backes WH, Griffioen AW et al (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63:1309–1315PubMedCrossRef de Lussanet QG, Backes WH, Griffioen AW et al (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63:1309–1315PubMedCrossRef
82.
Zurück zum Zitat Zahra MA, Tan LT, Priest AN et al (2009) Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74:766–773PubMed Zahra MA, Tan LT, Priest AN et al (2009) Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74:766–773PubMed
83.
Zurück zum Zitat Padhani AR, MacVicar AD, Gapinski CJ et al (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 218:365–374PubMed Padhani AR, MacVicar AD, Gapinski CJ et al (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 218:365–374PubMed
84.
Zurück zum Zitat Li W, Brophy DP, Chen Q et al (2000) Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. J Magn Reson Imaging 12:1004–1008PubMedCrossRef Li W, Brophy DP, Chen Q et al (2000) Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. J Magn Reson Imaging 12:1004–1008PubMedCrossRef
85.
Zurück zum Zitat O’Connor JP, Jackson A, Parker GJ et al (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189–195PubMedCrossRef O’Connor JP, Jackson A, Parker GJ et al (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189–195PubMedCrossRef
86.
Zurück zum Zitat Zweifel M, Padhani AR (2010) Perfusion imaging in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging. In press Zweifel M, Padhani AR (2010) Perfusion imaging in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging. In press
87.
Zurück zum Zitat Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRef Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRef
88.
Zurück zum Zitat Galbraith SM, Maxwell RJ, Lodge MA et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831–2842PubMedCrossRef Galbraith SM, Maxwell RJ, Lodge MA et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831–2842PubMedCrossRef
89.
Zurück zum Zitat Liu G, Rugo HS, Wilding G et al (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23:5464–5473PubMedCrossRef Liu G, Rugo HS, Wilding G et al (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23:5464–5473PubMedCrossRef
90.
Zurück zum Zitat Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572–4578PubMedCrossRef Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572–4578PubMedCrossRef
91.
Zurück zum Zitat Flaherty KT, Rosen MA, Heitjan DF et al (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496–501PubMed Flaherty KT, Rosen MA, Heitjan DF et al (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496–501PubMed
92.
Zurück zum Zitat Baar J, Silverman P, Lyons J et al (2009) A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 15:3583–3590PubMedCrossRef Baar J, Silverman P, Lyons J et al (2009) A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 15:3583–3590PubMedCrossRef
93.
Zurück zum Zitat Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRef Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRef
94.
Zurück zum Zitat Kamoun WS, Ley CD, Farrar CT et al (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542–2552PubMedCrossRef Kamoun WS, Ley CD, Farrar CT et al (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542–2552PubMedCrossRef
95.
Zurück zum Zitat Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16:167–172PubMed Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16:167–172PubMed
96.
Zurück zum Zitat Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91–101PubMedCrossRef Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91–101PubMedCrossRef
97.
Zurück zum Zitat Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47:601–606PubMedCrossRef Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47:601–606PubMedCrossRef
98.
Zurück zum Zitat Landis CS, Li X, Telang FW et al (2000) Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 44:563–574PubMedCrossRef Landis CS, Li X, Telang FW et al (2000) Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 44:563–574PubMedCrossRef
99.
Zurück zum Zitat Buckley DL (2002) Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magn Reson Med 47:420–424PubMedCrossRef Buckley DL (2002) Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magn Reson Med 47:420–424PubMedCrossRef
100.
Zurück zum Zitat Galbraith SM, Lodge MA, Taylor NJ et al (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132–142PubMedCrossRef Galbraith SM, Lodge MA, Taylor NJ et al (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132–142PubMedCrossRef
101.
Zurück zum Zitat Koh DM, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738PubMedCrossRef Koh DM, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738PubMedCrossRef
102.
Zurück zum Zitat Ashton E, Raunig D, Ng C et al (2008) Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions. J Magn Reson Imaging 28:791–796PubMedCrossRef Ashton E, Raunig D, Ng C et al (2008) Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions. J Magn Reson Imaging 28:791–796PubMedCrossRef
103.
Zurück zum Zitat Jackson A, O’Connor JP, Parker GJ et al (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13:3449–3459PubMedCrossRef Jackson A, O’Connor JP, Parker GJ et al (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13:3449–3459PubMedCrossRef
104.
Zurück zum Zitat Rose CJ, Mills SJ, O’Connor JP et al (2009) Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 62:488–499PubMedCrossRef Rose CJ, Mills SJ, O’Connor JP et al (2009) Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 62:488–499PubMedCrossRef
105.
Zurück zum Zitat Lee KC, Bradley DA, Hussain M et al (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003–1011PubMedCrossRef Lee KC, Bradley DA, Hussain M et al (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003–1011PubMedCrossRef
Metadaten
Titel
Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy
verfasst von
Anwar R. Padhani
Aftab Alam Khan
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Targeted Oncology / Ausgabe 1/2010
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-010-0135-8

Weitere Artikel der Ausgabe 1/2010

Targeted Oncology 1/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.